Home / Business and Economy / Braveheart Bio Eyes $1.2B IPO Valuation

Braveheart Bio Eyes $1.2B IPO Valuation

30 Jul

Summary

Braveheart Bio aims for a valuation up to $1.2 billion.
The company plans to raise $318.8 million in its IPO.
Shares will be offered between $15 and $17 each on Nasdaq.

Braveheart Bio, a clinical-stage biopharmaceutical company, is seeking a valuation of up to $1.2 billion through its upcoming U.S. initial public offering (IPO). The company announced its target valuation on Thursday, July 30, 2026.

Based in San Francisco, California, Braveheart Bio aims to generate $318.8 million from this IPO. The offering will consist of 18.8 million shares, with an anticipated price range of $15 to $17 per share. Goldman Sachs, Jefferies, TD Cowen, Stifel, and Cantor are serving as the joint bookrunners for this significant financial undertaking.

Upon successful completion of the IPO, Braveheart Bio intends to have its shares traded on the Nasdaq Global Market. The company will be listed under the stock symbol 'BRVE', marking its debut on a major stock exchange.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.